Vamsidhar Velcheti MD FAsCO FACP FCCP

Hematologic Oncology, Thoracic Cancer

Chair of Hematology and Oncology, Mayo Clinic in Jacksonville | Florida Department of Health Chair of Cancer Research

4500 San Pablo Rd SJacksonville, FL 32224
Phone+1 904-953-2000
Fax+1 212-731-5545

Dr. Velcheti is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Velcheti's full profile Already have an account?

Summary

Dr. Vamsidhar Velcheti is an oncologist based in Jacksonville, FL, with subspecialties in hematologic oncology and thoracic cancer. He completed his fellowship in hematology and medical oncology at Yale-New Haven Medical Center and his residency in internal medicine at Ochsner Clinic Foundation. He is currently an Associate Director at Cleveland Clinic and has experience in immunotherapy, hematologic oncology, lung cancer, thymoma, and granular cell tumors. Dr. Velcheti has been involved in numerous clinical trials and has published extensively on topics related to non-small cell lung cancer. His work has been recognized with several honors, including awards from the American Society of Clinical Oncology and Epic Systems Corporation.

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Ochsner Clinic FoundationResidency, Internal Medicine, 2007 - 2010
ArMed Forces Medical College PuneClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 2018 - 2028
FL State Medical License 2025 - 2027
OH State Medical License 2013 - 2019
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
Scott Hamilton CARES initiative research award 2015

Clinical Trials

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
COMPLETED
PHASE1
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
TERMINATED
PHASE2, PHASE3
Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung Start of enrollment: 2013 Apr 05
COMPLETED
PHASE2

Publications & Presentations

PubMed

Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.
Riddhi A Babel, Stephen V Liu, Tao Fan, Mayur M Amonkar, Vamsidhar Velcheti
Future Oncology. 2026-08-01
Phase III Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced or Metastatic NSCLC (ZEAL-1L).
Suresh S Ramalingam, Vamsidhar Velcheti, Mehmet Altan, Gilberto de Castro Jr, Michael Thomas
Journal of Thoracic Oncology. 2026-07-10
Current Roles of Neoadjuvant and Perioperative Immunotherapy in Non-Small Cell Lung Cancer.
Olivia Fankuchen, Salman Punekar, Vamsidhar Velcheti
JCO Oncology Practice. 2026-06-29

Books/Book Chapters

Oncologic Emergencies in The Washington Manual of Oncology.
Velcheti V and Govindan, RLippincott Williams & Wilkins, Philadelphia, PennsylvaniaEdition 2,
Lung Cancer in The Washington Sub-speciality Manual of hematology& Oncology.
Velcheti V and Subramanian, JLippincott Williams & Wilkins, Philadelphia, PennsylvaniaEdition 2,
Lung Cancer in Internal Medicine Just the facts.
Velcheti V and Govindan, RLippincott Williams & Wilkins, Philadelphia, PennsylvaniaEdition 2,

Abstracts/Posters

Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study
Vamsidhar Velcheti, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Retrospective EHR Study on Effectiveness of Eltrombopag in Cancer Treatment-Related Thrombocytopenia
Vamsidhar Velcheti, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Non-small cell lung cancer (NSCLC) in octogenarians.
Velcheti V., Viswanathan, A., Sainani, N., Grove, L., Suresh, R., Baggstrom, M.Q., and Govindan, R, Proc Am SocClinOnc, 2006; abst # 1855

Lectures

Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCL...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
Cytokines in Cancer Immunotherapy: Recent Updates
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Overcoming Resistance to Immune Checkpoint Blockade
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

WCLC 2021: Cracking the 'Undruggable' KRAS Problem in Lung CancerSeptember 2021
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020

Press Mentions

Biodesix Announces New Data on the VeriStrat® Test to Be Presented at the 2025 ASCO Annual MeetingMay 22nd, 2025
Asymptomatic Brain Metastases in EGFR-Mutant NSCLCDecember 20th, 2024
Taking on Acquired Resistance in EGFR-Mutant NSCLCNovember 1st, 2024

Grant Support

Novel Radiomics for Predicting Response to Immunotherapy for Lung CancerEMORY UNIVERSITY2021–2027
CHIRP Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersEMORY UNIVERSITY2018–2024
Computerized Histologic Risk Predictor (CHiRP) for early stage Lung Cancers Objectives: To develop and validate a computerized histologic risk predictor (CHiRP) to identify which early stage NSCLC patients, following surgery, will receive additional benefit from adjuvant chemotherapyNational institute of health2018–2023
Young Investigtator AwardAmerican Society of Clinical Oncology2012–2013

Committees

Member, Cancer Education Committee, American Society of Clinical Oncology 2015 - Present
Education Committee, American Society of Clinical Oncology 2015 - Present
Member, Protocol Review and Monitoring Committee, Case Comprehensive Cancer Center, Cleveland, Ohio 2014 - 2015
Member, Yale-New Haven Hospital-Graduate Medical Education Committee 2012 - 2013